ClinicalTrials.gg
CompletedNCT00396591Updated Jan 10, 2013Results posted

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

A Phase 2 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Ovarian Neoplasms, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-10.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Ovarian Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Ovarian Neoplasms · Sanofi.

Enrollment
11th of 13
16 · median 47
Started
2006
with 3 others
Phase 2
9 of 14
none open now
Registered
5th of 14
by date

Among the 14 studies in Ovarian Neoplasms by Sanofi, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2006, is one of 9 in phase 2, and was the 5th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 14 studies in Ovarian Neoplasms by Sanofi is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Ovarian Neoplasms by Sanofi as a file.
02

Study summary

The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic malignant ascites.

The secondary objectives were to further assess efficacy and safety of Aflibercept treatment, and the exploratory objectives were to assess pharmacokinetics, immunogenicity and health-related quality of life.

Read the detailed description

The study consisted of:

  • A 30-day screening phase prior to Day 1
  • Day 1 registration and pre-treatment paracentesis
  • Aflibercept administration within 1-day of registration
  • Two-week study treatment cycles (for efficacy data, the cut-off date was 6 months post-registration
  • A 60-day post-treatment follow-up phase

During the study, participants were treated with Aflibercept study treatment through the duration of the study unless they met one the following criteria for discontinuation:

  • Participant (or legal representative) chose to withdraw from treatment
  • The investigator or sponsor thought that continuation of the study would be detrimental to the participants well-being
  • Participant had intercurrent illness that prevented further administration of investigational product (IP)
  • Participant had more than 2 IP dose reductions
  • Participant had unacceptable adverse events (AEs)
  • Participant had arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset angina, or worsening of preexisting angina
  • Participant required surgical intervention for intestinal obstruction or gastrointestinal perforation
03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Ovarian cancer
  • malignant ascites
  • angiogenesis
  • angiogenesis inhibition
  • VEGF-Trap fusion recombinant protein
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants that met the following criteria were eligible.

Inclusion criteria

Inclusion Criteria:

  • Symptomatic malignant ascites resulting from advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) that required at least 3 previous therapeutic paracenteses at a frequency of 1 to 4 paracenteses per month for management.
  • Platinum resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance.
  • Topotecan- and/or liposomal doxorubicin-resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance.

Exclusion criteria

Exclusion Criteria:

  • Peritoneovenous or other type of shunt that was placed for the management of ascites
  • Prior treatment with a VEGF or VEGF receptor inhibitor
  • Uncontrolled hypertension

The above information is not intended to contain all considerations relevant to participation in a clinical trial.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Aflibercept

    Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met

    Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Repeat Paracentesis Response (RPR)

    RPR was defined as at least a two-fold increase in the time to repeat paracentesis (TRP) as compared to the average duration of the 2 intervals between the 3 most recent paracenteses prior to study registration (ie, the baseline interval of paracentesis). Percentage of participants with a repeat paracentesis response were the number of participants with RPR / number of total participants \* 100.

    Time frame: up to 2 years post-registration

Secondary outcomes

  1. Time to Repeat Paracentesis (TRP)

    TRP is the number of days between the date of registration and the date of the first postregistration paracentesis. Median TRP was estimated from Kaplan-Meier curves. For participants who did not undergo a postregistration paracentesis while on study, TRP was censored at the end of the treatment period (last dose + 1 cycle), at the last visit known without repeat paracentesis, at 6 months postregistration, or at death, whichever was earlier.

    Time frame: up to 6 months from registration

  2. 60-day Frequency of Paracentesis (FOP)

    FOP was the total number of paracenteses performed within the first 60 days postregistration. For participants who had withdrawn after registration but prior to the 60-day cutoff date, the withdrawal would have been regarded as a paracentesis event and the 60-day FOP normalized and calculated as the nearest integer of the value corresponding to 60 × number of paracenteses / x, where x represents the number of days on study.

    Time frame: up to 60 days post-registration

  3. Progression-free Survival (PFS) Time

    According to the Response Evaluation Criteria in Solid Tumors \[RECIST\], progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. PFS time was interval from the date of registration to the date of tumor progression or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. If participants were alive and progression-free at 6 months postregistration, they were censored for PFS.

    Time frame: up to 6 months post-registration

  4. Overall Survival (OS) Time

    OS time was the time interval between the date of registration to the date of death from any cause. Median OS was estimated from Kaplan-Meier curves. Participants who died after efficacy data cutoff date (6 months postregistration) were censored at the data cutoff date.

    Time frame: up to 6 months post-registration

  5. Number of Participants With a Positive Anti-drug Antibody Response

    Anti-drug antibodies in participant's serum were measured using 2 different methods * an Enzyme Linked Immunosorbent Assay (ELISA) in which the lower limit of detection (LLOD) was 238.4 ng/mL; and * an Electrochemiluminescence-based, Bridging Assay in which the validated LLOD was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept. Participants with detectable anti-drug antibodies by either method were considered to have a positive anti-drug antibody response.

    Time frame: up to 60 days after the last dose of treatment

  6. Safety - Number of Participants With Adverse Events (AE)

    All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

    Time frame: up to 60 days after last dose of treatment (approximately 2 years), or until TEAE was resolved or stabilized

07

Results

Posted Jan 10, 2013

Participant flow

17 participants were screened for this study, of which 16 participants were enrolled.

Participant flow — Overall Study
MilestoneAflibercept
Started16
Completed0
Not completed16
Withdrew: Disease progression13
Withdrew: Adverse event2
Withdrew: Participant request1

Outcome measures

PrimaryPercentage of Participants With a Repeat Paracentesis Response (RPR)

RPR was defined as at least a two-fold increase in the time to repeat paracentesis (TRP) as compared to the average duration of the 2 intervals between the 3 most recent paracenteses prior to study registration (ie, the baseline interval of paracentesis). Percentage of participants with a repeat paracentesis response were the number of participants with RPR / number of total participants \* 100.

Time frame:
up to 2 years post-registration
Reported as:
Number · percentage of participants
Percentage of Participants With a Repeat Paracentesis Response (RPR)
percentage of participantsAflibercept
Percentage of Participants With a Repeat Paracentesis Response (RPR)62.5 (35.43 to 84.80)
SecondaryTime to Repeat Paracentesis (TRP)

TRP is the number of days between the date of registration and the date of the first postregistration paracentesis. Median TRP was estimated from Kaplan-Meier curves. For participants who did not undergo a postregistration paracentesis while on study, TRP was censored at the end of the treatment period (last dose + 1 cycle), at the last visit known without repeat paracentesis, at 6 months postregistration, or at death, whichever was earlier.

Time frame:
up to 6 months from registration
Reported as:
Median · days
Time to Repeat Paracentesis (TRP)
daysAflibercept
Time to Repeat Paracentesis (TRP)76.0 (64.0 to 178.0)
Secondary60-day Frequency of Paracentesis (FOP)

FOP was the total number of paracenteses performed within the first 60 days postregistration. For participants who had withdrawn after registration but prior to the 60-day cutoff date, the withdrawal would have been regarded as a paracentesis event and the 60-day FOP normalized and calculated as the nearest integer of the value corresponding to 60 × number of paracenteses / x, where x represents the number of days on study.

Time frame:
up to 60 days post-registration
Reported as:
Mean · paracenteses
60-day Frequency of Paracentesis (FOP)
paracentesesAflibercept
60-day Frequency of Paracentesis (FOP)1.5 ± 1.6
SecondaryProgression-free Survival (PFS) Time

According to the Response Evaluation Criteria in Solid Tumors \[RECIST\], progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. PFS time was interval from the date of registration to the date of tumor progression or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. If participants were alive and progression-free at 6 months postregistration, they were censored for PFS.

Time frame:
up to 6 months post-registration
Reported as:
Median · days
Progression-free Survival (PFS) Time
daysAflibercept
Progression-free Survival (PFS) Time59.5 (41.0 to 83.0)
SecondaryOverall Survival (OS) Time

OS time was the time interval between the date of registration to the date of death from any cause. Median OS was estimated from Kaplan-Meier curves. Participants who died after efficacy data cutoff date (6 months postregistration) were censored at the data cutoff date.

Time frame:
up to 6 months post-registration
Reported as:
Median · days
Overall Survival (OS) Time
daysAflibercept
Overall Survival (OS) Time92.0 (58.0 to NA)
SecondaryNumber of Participants With a Positive Anti-drug Antibody Response

Anti-drug antibodies in participant's serum were measured using 2 different methods * an Enzyme Linked Immunosorbent Assay (ELISA) in which the lower limit of detection (LLOD) was 238.4 ng/mL; and * an Electrochemiluminescence-based, Bridging Assay in which the validated LLOD was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept. Participants with detectable anti-drug antibodies by either method were considered to have a positive anti-drug antibody response.

Time frame:
up to 60 days after the last dose of treatment
Reported as:
Number · participants
Number of Participants With a Positive Anti-drug Antibody Response
participantsAflibercept
Number of Participants With a Positive Anti-drug Antibody Response0
SecondarySafety - Number of Participants With Adverse Events (AE)

All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

Time frame:
up to 60 days after last dose of treatment (approximately 2 years), or until TEAE was resolved or stabilized
Reported as:
Number · participants
Safety - Number of Participants With Adverse Events (AE)
participantsAflibercept
With at least one TEAE16
With at least one serious TEAE15
With a TEAE leading to death8
With a TEAE resulting in discontinuation2

Adverse events

Collected over From treatment initiation to January 30, 2009. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept—15/16 (93.8%)16/16 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventAflibercept
Intestinal obstructionGastrointestinal disorders5/16
VomitingGastrointestinal disorders4/16
Disease progressionGeneral disorders4/16
NauseaGastrointestinal disorders2/16
AnaemiaBlood and lymphatic system disorders1/16
TachyarrhythmiaCardiac disorders1/16
Abdominal painGastrointestinal disorders1/16
Intestinal perforationGastrointestinal disorders1/16
Large intestinal obstructionGastrointestinal disorders1/16
Small intestinal obstructionGastrointestinal disorders1/16
Most frequent other events
Showing 10 of 64
Most frequent other events
EventAflibercept
VomitingGastrointestinal disorders8/16
HypertensionVascular disorders7/16
Abdominal painGastrointestinal disorders6/16
NauseaGastrointestinal disorders6/16
AstheniaGeneral disorders5/16
Disease progressionGeneral disorders5/16
AnorexiaMetabolism and nutrition disorders5/16
FatigueGeneral disorders4/16
ConstipationGastrointestinal disorders3/16
Oedema peripheralGeneral disorders3/16

Baseline characteristics

Age Continuous
Age Continuous(years)Aflibercept
Mean59.3 ± 8.9
Age, Customized
Age, Customized(participants)Aflibercept
<65 years11
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept
Female16
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aflibercept
Caucasian16
Primary tumor site - Ovaries
Primary tumor site - Ovaries(Participants)Aflibercept
Number16
Time since initial cancer diagnosis
Time since initial cancer diagnosis(Years)Aflibercept
Mean2.8 ± 1.7
Histology
Histology(Participants)Aflibercept
Serous9
Endometrioid3
Clear cell (mesonephroid)1
Other1
Missing data2
Histology grade
Histology grade(Participants)Aflibercept
Unknown5
Moderately differentiated1
Poorly differentiated10

3 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
09

References and documents

Publications

  • Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, Chamberlain D. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 2012 Apr;125(1):42-7. doi: 10.1016/j.ygyno.2011.11.021. Epub 2011 Nov 21. PubMed 22112608 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 4 years 2 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2006
First posted
Nov 7, 2006
Start
Oct 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results delay requested
Jul 21, 2011
Results first posted
Jan 10, 2013
Last update
Jan 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396591
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 7, 2006
Start date
Oct 2006
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Jan 10, 2013
Last update
Jan 10, 2013

Study contacts

ICD
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion